NB11 Stock Overview
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Vaxart, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.32 |
| 52 Week High | US$1.05 |
| 52 Week Low | US$0.26 |
| Beta | 1.28 |
| 1 Month Change | 11.33% |
| 3 Month Change | -54.59% |
| 1 Year Change | -52.52% |
| 3 Year Change | -89.36% |
| 5 Year Change | -87.10% |
| Change since IPO | -53.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| NB11 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.6% | 0.6% | 1.7% |
| 1Y | -52.5% | -12.2% | 12.8% |
Return vs Industry: NB11 underperformed the German Biotechs industry which returned -13.8% over the past year.
Return vs Market: NB11 underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| NB11 volatility | |
|---|---|
| NB11 Average Weekly Movement | 19.7% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: NB11's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NB11's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 105 | Steven Lo | vaxart.com |
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Vaxart, Inc. Fundamentals Summary
| NB11 fundamental statistics | |
|---|---|
| Market cap | €76.31m |
| Earnings (TTM) | -€59.18m |
| Revenue (TTM) | €25.37m |
3.1x
P/S Ratio-1.3x
P/E RatioIs NB11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NB11 income statement (TTM) | |
|---|---|
| Revenue | US$28.70m |
| Cost of Revenue | US$74.21m |
| Gross Profit | -US$45.51m |
| Other Expenses | US$21.44m |
| Earnings | -US$66.95m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 13, 2025
| Earnings per share (EPS) | -0.29 |
| Gross Margin | -158.58% |
| Net Profit Margin | -233.27% |
| Debt/Equity Ratio | 9.8% |
How did NB11 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 07:11 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaxart, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Roger Song | Jefferies LLC |
| Cheng Li | Oppenheimer & Co. Inc. |